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Abstract Proteolytic processing of P-amyloid precursor protein 
(APP) is believed to be fundamental to the understanding of 
Alzheimer's disease. The identities and the regulatory elements 
of the proteases involved in the process, known as ct/p/y 
secretases, are unclear. In this study, by examining reported 
data, we found some indications suggesting that the putative a-
secretase may be a calcium-dependent protease, and that this 
enzyme may play a primary role in the regulation of APP 
processing. Based on this, we proposed a model for the membrane 
orientations of the secretases for further discussions. 
© 1997 Federation of European Biochemical Societies. 
Key words: Alzheimer; (3-Amyloid; Secretase; Calcium; 
Calpain 
1. Introduction 
Alzheimer's disease (AD) is characterized by the presence of 
amyloid plaques and neurofibrillary tangles in the brain. 
Amyloid plaques are mainly comprised of P-amyloid peptide 
(Ap), which is a proteolytic product of P-amyloid precursor 
protein (APP). In normal individuals, processing of APP in-
volves predominantly cleavage within the AP domain at the 
Lys16 site by a putative a-secretase, thereby precluding the 
formation of intact Ap. In patients with AD, APP is exces-
sively cleaved at both ends of Ap by P- and y-secretases [1,2]. 
The reasons for this are unclear. A number of proteases has 
been proposed to be candidates for these secretases thus far, 
but a consensus has not been reached over their enzyme clas-
sifications or regulatory elements [3,4]. This issue is important 
to the disease origin since the overproduction of AP precedes 
its damaging effects to the cells. Attempts to resolve this issue 
have been complicated primarily by: difficulties in tracing 
enzyme action in situ; complexity of protease specificity; 
and continuing discrepancies over the putative regulatory el-
ements involved. In this study, we present evidence to suggest 
some characteristics of the secretases. 
2. a-Secretase may be a calcium-dependent protease 
We examined a number of reports regarding the regulation 
of APP processing in various cells. These studies have shown 
that secretion of soluble APP (APPS) from cells can be af-
fected by a wide variety of agents. By sorting through the 
reported data, we noticed that agents that increase APPS se-
cretion include the following: phorbol esters [5], thapsigargin 
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[5], calcium ionophores [6], carbachol [7], thrombin [8], inter-
leukin-1 (IL-1) [9], acetylcholine (ACh) [9], basic fibroblast 
growth factor (bFGF) [10], lipopolysaccharide (LPS) [11], in-
domethacin [12], serotonin [13], estrogen [14], bradykinin [15], 
melittin [16], glutamate [17], electrical depolarization [18] and 
others. These agents have a wide diversity of biochemical and 
physiological effects. For example, glutamate and serotonin 
are neurotransmitters, and indomethacin is a cyclooxygenase 
inhibitor. Authors of these reports have attributed the ob-
served effects on APPS secretion to the best known actions 
of the respective agents, such as activation of neurotransmit-
ter receptor, arachidonate metabolism, and so on. A common 
pathway has not been identified. 
By examining the known actions of each agent individually, 
it came to our attention that the above 16 agents manifest at 
least one unifying effect. Each of them is able to elevate intra-
cellular calcium levels, either through transmembrane influx 
or through release from intracellular stores [5-7,17-28]. This 
effect is well-known for some of these agents, i.e. calcium 
ionophore [6], phorbol esters [5], thapsigargin [5], carbachol 
[7], thrombin [19], ACh [21], bFGF [22], estrogen [26], brady-
kinin [27], glutamate [17] and electric depolarization [18]. The 
cellular effects of these agents are known to be mediated by 
calcium mobilization. For others, the calcium-elevating effect 
may not be as well-known, but has been experimentally con-
firmed (LPS [23], indomethacin [25], IL-1 [20], melittin [28], 
serotonin [24]). Whereas most of these studies have not con-
sidered the calcium effect to be the primary factor affecting 
APPS secretion, Buxbaum et al. [5] have pointed out that the 
effect of the agents (phorbol esters, IL-1, thapsigargin and 
carbachol) on APPS secretion is due to calcium changes and 
can be independent of protein kinase C activation. 
Calcium ionophore has also been reported to increase Ap 
secretion [29]. Since a corresponding decrease of APPS has not 
been observed in this report, the finding may not necessarily 
conflict with the other reports (e.g. [6]). It is possible that this 
effect on Ap could be due to the highly sensitive detection by 
radioimmunoprecipitation of minor AP changes induced by a 
slight activation of cellular exocytosis under the conditions 
used. Indeed, the increase of Ap is only associated with low 
concentrations of the ionophore (0.1-0.5 U.M) and higher con-
centrations of the ionophore (1-5 \xM) have resulted in a 
decline of AP [29]. Presumably, a simultaneous determination 
of both APPS and Ap released from the same cells will resolve 
this discrepancy. 
In concert with the effect of the above 16 calcium-elevating 
agents, another group of agents that can offset or oppose the 
calcium effects under certain circumstances, such as cAMP, 
forskolin, cholera toxin [30], nordihydroguaiaretic acid 
(NDGA) [31], brefeldin A [32] and atropine [21], have been 
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observed to decrease APPS secretion (cAMP, forskolin [33,34], 
cholera toxin [33], NDGA [12], brefeldin A [35], atropine [9]). 
The effects of these six agents on calcium are also known. 
NDGA, for example, suppresses calcium elevation induced 
by glutamate [31]. Brefeldin A exerts its effect by sequestering 
calcium to intracellular stores [32]. We and others have pre-
viously shown that the cAMP-related signal pathway is able 
to oppose the effects of the phospholipase C/Ca2+ pathway in 
some cell types (but not universally) [33,34,36,37]. It has been 
noted that the effects of some of the agents are concentration-
dependent and sometimes cell-type specific. cAMP has also 
been observed to increase APPS secretion [38], probably with 
a different time frame and under different conditions from 
those used in other reports [33,34]. Lee et al. [34] have shown 
that cAMP can also increase APP gene expression. 
Based on the bulk of the experimental data, it can be in-
ferred that there is a previously unknown (or not generalized) 
and intimate correlation between the free intracellular calcium 
levels and APPS secretion. As calcium is an important factor 
regulating many life processes, this correlation may suggest 
some interesting features of APP processing. 
Elevation of the intracellular calcium levels can elicit several 
responses [39]. Among those, neuronal excitability and activa-
tion of protein kinases are unable to uniformly and directly 
explain the observed effects in different cells. Also, cellular 
exocytosis can be activated by calcium and contribute to the 
increased release of intracellular proteins. Exocytosis itself, 
however, would not account for the increased secretion of 
APPS that has been proteolytically cleaved from its precursor, 
the full-length APP. 
It seems that the correlation between calcium levels and 
APPS secretion would not be reasonably explained without 
the implication of a protease, which cleaves APP within the 
Ap domain to produce APPS. By definition this protease is the 
putative a-secretase, and the observed APPS changes are a 
measure of the activity of that protease. Although most of 
these studies have not determined the actual cleavage site of 
APPS, it is likely that its C-terminus predominantly ends at 
Lys16 of A|3. Direct biochemical sequencings of APPS from a 
variety of cells including yeast have found only this form of 
APPS as the predominant species [40-45]; thus other shorter 
or longer APPS derivatives, being detected only by radio-se-
quencings, should be minor [46]. Sisodia and others have 
shown that a-secretase is a highly specific protease which 
acts only at the APP sites having certain distances from the 
membrane [47-49]. 
Thus, a reasonable explanation for the observed correlation 
between calcium levels and APPS would be that the elevation 
of calcium activates, among other things, the putative a-sec-
retase. Synergistic cooperation of this protease and cellular 
exocytosis would account for the observed increase of APPS 
secretion. As such, the regulatory mechanism of a-secretase 
should be calcium-dependent. It is noteworthy that the regu-
latory mechanism of a-secretase by calcium is characterized 
by high sensitivity (some agents elicit a moderate Ca2+ tran-
sient), reliability (repeatedly observed under a diversity of ex-
perimental conditions: temperature, action duration and 
measurement methods) and ubiquity (found in a wide variety 
of cell types: peripheral and neuronal, natural and recombi-
nant). 
3. A model for membrane orientations of a-, p- and y-secretases 
3.1. a-Secretase 
If a-secretase is a calcium-dependent protease, then mem-
brane orientation of APP would suggest that this enzyme 
would have access to cytosol and meanwhile be able to reach 
the Lys16 site (a-secretase site) located at the outside surface 
of the plasma membrane (or in the lumen of Golgi apparatus 
where most secretory proteins are processed [50], including a-
cleavage of APP [3,51] (Fig. 1). As such, it should be a mem-
brane-associated (or transmembrane) protease, in line with a 
known feature of a-secretase [47]. Interestingly, such an un-
usual double membrane anchorage of both an enzyme and its 
substrate would impose a rigid steric restraint at the cleavage 
site relative to the membrane, due to hindrance of free move-
Cytosol 
Fig. 1. A proposed model for membrane orientations and subcellular localizations of a-, P- (and p-like) and y-secretases. The schematic repre-
sentation is intended to show that: (1) APP, a- and y-secretases are located in the membranes of both plasma and intracellular organelles (Gol-
gi, endoplasmic reticulum or endosome/lysosome; only Golgi is shown), and a-secretase is a transmembrane protease regulated by calcium in 
the cytosol; (2) double membrane anchorage of both a-secretase and APP may impose a 'distance-over-sequence' preference during the cleav-
age of APP by a-secretase; (3) p-like secretases (p-secretase and other proteases that produce AP-containing fragments) (arrowheads) should be 
found in ECM or in the lumen of the intracellular organelles; (4) membrane association of y-secretase and its likely contact by a-secretase may 
give it freedom of mobility and sensitivity to steric distortions (e.g. APP717 mutations) that may somehow cause y-secretase 'swinging' along 
the hydrophobic residues of APP to produce longer AP (see Fig. 2). 
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Fig. 2. Flexibility of y-secretase. Compared with a normal pair of 
enzyme (E)/substrate (S)(A), the recognition of y-secretase (y) to 
APP (B) is additionally influenced by the binding of the enzyme to 
the membrane (M). Such a binding may render the enzyme more 
freedom of mobility relative to APP. It is possible that APP717 mu-
tations (at A|345 or A|346) might alter the conformation of APP 
that normally holds y-secretase at the Ap40 position, thereby allow-
ing the enzyme to move. 
ment. This can explain the elegant observations that oc-secre-
tase has a 'distance-over-sequence' preference during its cata-
lytic action, in which the enzyme only acts at sites 12-13 
amino acids from the membrane [47—49]. 
However, calcium-dependent proteases, to our knowledge, 
have not been considered thus far to be candidates for oc-
secretase, though such proteases (e.g. calpain) have been sug-
gested as possible (3-like secretases [4,52,53]. Whereas the dis-
crepancy awaits clarification, here we consider some known 
features of P-secretase. 
3.2. [5-Like secretases 
The membrane orientation of APP (Fig. 1) also suggests 
that the p-like secretases (including P-secretase and those 
cleaving at upstream sites of APP) should be located in the 
extracellular milieu (ECM) or in the lumen of intracellular 
organelles. Cytosolic enzymes cannot have access to the P-
secretase site, or to the upstream sites of APP to generate 
the Ap-containing fragments (8, 12 kDa or larger). Such frag-
ments are physiologically produced [3,54] and would not be 
explained by postulating that a membrane damage leaks the 
cytosolic enzymes to ECM. 
As extracellular enzymes, P-like secretases will not be sen-
sitively regulated by calcium, because calcium concentration 
in ECM is 10000-fold higher than in cytosol [50]. Sensitive 
regulation of an enzyme by a cellular element requires that the 
element and the enzyme should both be located in a compart-
ment in which the element concentration is low (cytosol), and 
that there is a large gradient outside tending to drive the 
element across the membrane into that compartment. The 
high calcium levels in ECM cannot be significantly changed 
by any stimuli and thus P-like secretases would not explain the 
sensitive response of APP processing to the various agents. 
Alternatively, P-like secretases can function in the lumen of 
endoplasmic reticulum (not shown) or Golgi apparatus (Fig. 
1) where APP processing by P-secretase has been observed 
[51]. Calcium levels in these organelles are also high, since 
they are actually the intracellular calcium stores [32,50]. 
Also, P-processing of APP may occur in endosome/lysosome 
(not shown; but the same orientations as in Golgi) [55]. Cal-
cium levels in these compartments are high as well, because 
they are formed by endocytosis of ECM (along with the in-
ternalized APP on the plasma membrane) or derived from 
Golgi, thus they are equivalent to ECM or Golgi in the in-
gredients [50]. 
Therefore, it appears that the p-like secretases in any of 
these locations are unlikely to be sensitively regulated by cal-
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cium. Indeed, sensitive regulation of calpain, the best known 
calcium-dependent protease, has only been found to function 
physiologically in the cytosol or in the membrane-associated 
sites in touch with cytosol [56]. 
Can P-secretase be a transmembrane protease (similar to 
the model of a-secretase as we proposed)? Clearly, such a 
protease would first reach the Lys16 site (12 amino acids 
from the membrane) before it can reach the P-secretase site 
(28 amino acids from the membrane), if it can do so at all 
(Fig. 1). In other words, this protease would only be able to 
act as a-secretase rather than p-secretase, because the mem-
brane-bound secretase has an out-reaching limit of only 12-13 
amino acids from the membrane and no cleavage at the up-
stream sites has been found [47^19]. 
As calpain is membrane-associated when activated in vivo, 
an interesting question is: can calpain act as oc-secretase? We 
have recently observed that non-amyloidogenic cleavage of 
APP at or near Lys16 in a cell-free system is mediated by a 
calcium-dependent protease (unpublished data). However, it is 
unclear whether calpain, as a cytosolic enzyme only known to 
be associated with the inner surface of the membrane, can 
'protrude' to the cell surface. If calpain is uncertain even to 
act as a-secretase, then the possibility of it acting as P-secre-
tase, or as other enzymes that have to reach the sites far up-
stream to produce the amyloidogenic fragments, could per-
haps be ruled out. 
3.3. y-Secretase 
y-Secretase exhibits a peculiar flexibility in its substrate spe-
cificity. Since it can cleave the APP sites within the membrane 
under physiological conditions, it is reasonable to assume that 
it is also a membrane-associated protease (Fig. 1). In this 
model, the membrane-binding of y-secretase would render 
the enzyme more freedom of mobility relative to APP (Fig. 
2). Also, the membrane-associated a- and y- secretases, acting 
on the same substrate, would be in a close proximity (likely 
contacted) within a short distance on APP between the two 
enzymes' acting sites (24 residues between Lys16 and Val40) 
relative to the much larger masses of the proteases themselves 
(Fig. 1). Such a 'cluster' of the membrane proteins would be 
expected to be sensitive to any distortions (e.g., APP717 mu-
tations [57]), which might exert their effects by somehow 'dis-
locating' y-secretase (probably through a changed APP con-
formation which normally hold y-secretase in place) from 
Val40 to Ala42 [3,58]. Alternatively, a second y-like secretase 
may be responsible for the genesis of AP42; but the limited 
space of only two animo acids on APP may make it difficult 
to accommodate two separate enzymes (or several enzymes 
since Ap39,41,43 are also observed). 
If a-secretase is calcium-dependent, then neither P- nor y-
secretase would be regulated by the same signal. Studies have 
shown that an increased APPS level in vivo is accompanied by 
a decreased Ap [59] and vice versa [60], suggesting that ce-
secretase and p/y-secretases act reciprocally competing for 
the same pool of the full-length APP. This implies that neither 
P- nor y-secretase could be a calcium-dependent protease. 
4. a-Secretase may be the primary determinant in APP 
processing 
If a-secretase is a calcium-dependent protease, then this 
would imply that a-secretase is regulated in vivo more sensi-
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Fig. 3. APP mutations and their consequences. A: Reported APP 
missense mutations. The three secretase sites are denoted as a, p 
and y, respectively. B: The relationships between the distances of 
the mutations relative to the a-secretase site, their clinical conditions 
and A|3 level changes in their hosts. Note that the distances of the 
mutations to the Lys16 site correspond to an increasing severity of 
the conditions and roughly to increasing Ap levels. Mutations 'out-
side AP' are inferred from the absence of such clinical cases; 'both 
end', the Swedish and APP717 types; 'inside AP', the Dutch type. 
The Ap levels are deduced from the reports (particularly in the 
brain vessels). Prem., premature. 
tively than p/y-secretases since Ca2+ is perhaps the most sen-
sitive cellular signal that can directly regulate proteases (most 
proteases are unregulated though they can be affected by less 
sensitive factors such as gene expression and pH changes) [61]. 
It seems likely that a-secretase is primarily responsible for the 
effects of the various agents that affect APP processing [3,4] 
(see also above), and thus plays a dominant role in the regu-
lation of APP processing in vivo. 
This possibility appears to be consistent with the genetic 
studies. Familial AD phenotypes have been segregated with 
APP gene missense mutations. If a-secretase plays a primary 
role in APP processing, then mutations occurring at different 
'distances' relative to the a-secretase site would be expected to 
result in different A[3 levels and distinct pathological conse-
quences in their hosts (Fig. 3A). There may be such a phe-
nomenon. 
First, mutations are typically located at or near the A(3 
domain (the Swedish and APP717 types at both ends of A(3 
[57,62]) since this is where they can affect the outcome of the 
secretase cleavages. Logically, mutations occurring far outside 
the A(3 domain would not affect the cleavage as much and 
may not be pathological. Second, mutations that occur in 
closer proximity to Lys16 than the Swedish and APP717 types 
cause more severe conditions than the latter two types. Dutch-
type mutations at Glu22 and Ala21 cause hemorrhage with a 
'severe amyloidosis' in the blood vessels and 'early death' of 
their hosts in the fifth or sixth decade (typical AD patients 
have a normal life expectancy) [58,63,64]. Third, this trend 
would suggest that if mutations occur directly at the Lys16 
site, they are probably fatal (lethal). In fact, such natural 
mutations have not been reported, but Moechars et al. [65] 
have shown that artificial mutations at this site have resulted 
in 'premature death' in transgenic animals, suggesting that 
such mutations are not tolerated in humans. The relationships 
between these mutations and their phenotypes are summar-
ized in Fig. 3B. Notably, an increasing severity of the pheno-
types also seems to correspond to the A|3 level (the A(3 level in 
the Lys16 mutant animals might be high as well and might 
have been deposited had the animals lived longer, because the 
mutant APPS secretion is reduced by ~ 50% [65]). 
Such a 'proximity rule' relative to a-secretase site, but not 
to the |3/y-secretase sites, suggests that: (1) AD phenotypes 
caused by known APP mutations are primarily due to the 
perturbation of a-secretase function; (2) p/y-secretase func-
tions may not be as important in causing the phenotypes (if 
they were important, then Dutch types and Lys16 mutations, 
which have moved away from the p/y-secretase sites, would 
cause lower levels of Ap and less severe conditions than the 
Swedish and APP717 types); (3) the functional integrity of a-
secretase on APP can have far-reaching consequences in the 
body. 
Whereas the mechanisms and implications behind these 
phenomena can be profound, the leading role of a-secretase 
in the phenotype development, together with its regulation by 
calcium, appears to support the possibility that this enzyme is 
the primary determinant in the competition with its p/y-coun-
terparts for the outcome of APP processing. 
If our interpretations of the reported data are correct, then 
they would imply that a-secretase should receive more atten-
tion in the attempts to understand the abnormal processing of 
APP in AD. The regulatory mechanism of this enzyme may 
have important implications in the understanding of AD 
pathogenesis [66]. As the issues are controversial, it is hoped 
that the views presented here, many of which are from a 
theoretical perspective, will induce further discussions about 
these issues. 
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